Pharvaris (PHVS) Long-Term Deferred Tax (2020 - 2026)
Pharvaris (PHVS) reported Long-Term Deferred Tax of $875169.8 for Q1 2026, up 123.46% on a YoY basis from $391638.7 in Q1 2025, and down 15.27% quarter-over-quarter from $1.0 million in Q4 2025.
Pharvaris (PHVS) Long-Term Deferred Tax (2020 - 2026) Analysis & Trends
Pharvaris has reported Long-Term Deferred Tax for 7 years, with the latest figure at $875169.8 in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Deferred Tax rose 123.46% year-over-year to $875169.8; the trailing twelve-month figure through Mar 2026 stood at $875169.8 (up 123.46% YoY), and the FY2025 full-year result was $1.0 million, up 95.27% from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $875169.8, down from $1.0 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $1.0 million in Q4 2025, with the low at $96667.3 in Q1 2023.
- Historically, Long-Term Deferred Tax has averaged $385868.2 across 5 years, with a median of $337180.2 in 2025.
- Annual changes were most pronounced in 2023 — Long-Term Deferred Tax tumbled 36.97% — and 2024, when it soared 345.14%.
- Pharvaris' Long-Term Deferred Tax stood at $265063.3 in 2022, then jumped by 57.31% to $416957.9 in 2023, then increased by 21.57% to $506885.0 in 2024, then jumped by 103.78% to $1.0 million in 2025, then declined by 15.27% to $875169.8 in 2026.
- The last three Long-Term Deferred Tax figures came in at $875169.8 (Q1 2026), $1.0 million (Q4 2025), and $535260.1 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Pharvaris | 28.66 Bn | 28.37 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 875,169.84 |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 535,260.06 |
| Jun 30, 2025 | 337,180.23 |
| Mar 31, 2025 | 391,638.67 |
| Dec 31, 2024 | 506,885.02 |
| Sep 30, 2024 | 267,827.18 |
| Jun 30, 2024 | 373,271.85 |
| Mar 31, 2024 | 430,304.64 |
| Dec 31, 2023 | 416,957.92 |
| Sep 30, 2023 | 329,461.91 |
| Jun 30, 2023 | 199,831.78 |
| Mar 31, 2023 | 96,667.31 |
| Dec 31, 2022 | 265,063.33 |
| Sep 30, 2022 | 241,413.14 |
| Jun 30, 2022 | 106,547.74 |
| Mar 31, 2022 | 153,362.96 |
| Dec 31, 2021 | 196,823.63 |
| Sep 30, 2021 | 138,139.36 |
| Jun 30, 2021 | 123,526.94 |